Related Experiment Video
Updated: Jun 19, 2026
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Published on: September 15, 2023
NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide
Lucas Minig1, Edward L Trimble, Michael J Birrer
1National Cancer Institute, Bethesda, MD 20892, USA.
Abstract:
The development of novel therapeutics is a lengthy and often tortuous process. It frequently spans the identification of new targets, preclinical validation, discovery and refinement of novel therapies, safety studies, phase O, 1, 2, and 3 trials, and reverse translation. NIH and NCI provide via web sites a variety of resources and research tools of great value to investigators. NCI also provides tissue resources useful for discovery and validation, as well as extensive support for preclinical drug development. The NCI's effective partnership with industry and academia, as well as the ongoing NCI-supported clinical trials network, facilitates clinical development of novel therapeutics. Specialized NCI programs focused on cancer imaging, radiation research, and complementary and alternative medicine, also assist the development of novel agents. Finally, the NIH and the NCI sponsor a variety of grant mechanisms, supporting institutions, consortia, and individuals, which investigators seeking to develop novel therapeutics should make themselves familiar.
Insights
Developing novel therapeutics is a complex journey. The National Cancer Institute (NCI) offers valuable resources and support throughout the entire drug development process, from discovery to clinical trials.
Area of Science:
- Drug Development
- Oncology Research
- Therapeutic Innovation
Background:
- Novel therapeutic development is a complex, multi-stage process.
- This process includes target identification, preclinical validation, clinical trials (Phase 0-3), and reverse translation.
- Numerous challenges exist throughout the lengthy drug development pipeline.
Purpose of the Study:
- To highlight the extensive resources and support systems available for developing novel therapeutics.
- To inform investigators about the National Institutes of Health (NIH) and National Cancer Institute (NCI) initiatives.
- To guide researchers in navigating the drug development pathway.
Main Methods:
- Review of NIH and NCI resources and programs.
- Identification of support mechanisms for preclinical and clinical development.
- Examination of NCI's role in facilitating therapeutic advancement.
Main Results:
- NIH and NCI provide essential web resources, research tools, and tissue repositories.
- NCI actively supports preclinical drug development and offers extensive clinical trial networks.
- Specialized NCI programs enhance the development of novel therapeutic agents.
Conclusions:
- Investigators should leverage NIH and NCI resources, including grant mechanisms, for developing novel therapeutics.
- NCI's partnerships and programs significantly facilitate the clinical development of new cancer treatments.
- Familiarity with NCI-supported initiatives is crucial for successful therapeutic innovation.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:27Nursing Clinical Information System
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...